<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1900">
  <stage>Registered</stage>
  <submitdate>24/03/2008</submitdate>
  <approvaldate>24/03/2008</approvaldate>
  <nctid>NCT00644982</nctid>
  <trial_identification>
    <studytitle>A Comparison of Sertraline Versus Venlafaxine XR in the Treatment of Major Depression</studytitle>
    <scientifictitle>A Multicenter Randomized, Double-Blind, Parallel-Group Study of Sertraline Versus Venlafaxine XR in the Acute Treatment of Outpatients With Major Depressive Disorder</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>A0501066</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Depressive Disorder, Major</healthcondition>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Depression</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - sertraline
Treatment: drugs - venlafaxine XR

Experimental: Sertaline group - 

Active Comparator: Venlafaxine group - 


Treatment: drugs: sertraline
Flexibly-titrated 50 mg tablets, 50-150 mg/day and venlafaxine placebo orally for 10 weeks.

Treatment: drugs: venlafaxine XR
Flexibly-titrated 75 mg capsules, 75-225mg/day and sertraline placebo orally for 10 weeks.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change from baseline in QOL, measured using the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q).</outcome>
      <timepoint>Weeks 1, 2, 3, 4, 6, 8, 9 and 10.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in the 17-item Hamilton-Depression Rating Scale (HAM-D) including response (=50% reduction in HAM-D total score from baseline) and remission (HAM-D total score =7) rates.</outcome>
      <timepoint>Weeks 1, 2, 3, 4, 6, 8, 9 and 10.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The 17-item Hamilton-Depression Rating Scale response rates at endpoint (week 8).</outcome>
      <timepoint>Week 8</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>CGI response rate at endpoint (week 8).</outcome>
      <timepoint>Week 8</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in the CGI-Severity Scale (CGI-S).</outcome>
      <timepoint>Weeks 1, 2, 3, 4, 6, 8, 9 and 10.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in the Hamilton Anxiety Scale (HAM-A).</outcome>
      <timepoint>Weeks 1, 2, 3, 4, 6, 8, 9 and 10.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in the Endicott Work Productivity Scale (EWPS).</outcome>
      <timepoint>Weeks 1, 8, 9, 10</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in the Visual Analogue Scale (VAS) for Depression.</outcome>
      <timepoint>Weeks 1, 2, 3, 4, 6, 8, 9 and 10.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in the Visual Analogue Scale (VAS) for Overall Assessment of Pain.</outcome>
      <timepoint>Weeks 1, 2, 3, 4, 6, 8, 9 and 10.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Hamilton-Depression Rating Scale remission rates at endpoint (week 8).</outcome>
      <timepoint>Week 8</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in the Clinical Global Impression-Improvement Scale.</outcome>
      <timepoint>Weeks 1, 2, 3, 4, 6, 8</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Primary diagnosis of DSM-IV Major Depressive Disorder, single episode or recurrent,
             without psychotic features. Additional DSM-IV Axis I diagnoses will be permitted only
             if they are identified as secondary diagnoses.

          -  Hamilton-Depression rating scale (HAM-D; 17 item) total score =18 and HAMD item 1
             (depressed mood) score =2.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Use of an antidepressant within 2 weeks of baseline (4 weeks for fluoxetine)

          -  Current or past diagnosis of bipolar disorder or any psychotic disorder.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/10/2002</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>163</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/09/2003</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD,VIC,WA</recruitmentstate>
    <hospital>Pfizer Investigational Site - Cairns</hospital>
    <hospital>Pfizer Investigational Site - Everton Park</hospital>
    <hospital>Pfizer Investigational Site - North Cairns</hospital>
    <hospital>Pfizer Investigational Site - Box Hill</hospital>
    <hospital>Pfizer Investigational Site - Heidelberg</hospital>
    <hospital>Pfizer Investigational Site - West Heidelberg</hospital>
    <hospital>Pfizer Investigational Site - West Perth</hospital>
    <postcode>4870 - Cairns</postcode>
    <postcode>4053 - Everton Park</postcode>
    <postcode>4870 - North Cairns</postcode>
    <postcode>3128 - Box Hill</postcode>
    <postcode>3084 - Heidelberg</postcode>
    <postcode>3081 - West Heidelberg</postcode>
    <postcode>6005 - West Perth</postcode>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Adana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Ankara</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Diyarbakir</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Istanbul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Izmir</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Izmit</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Malatya</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Pfizer</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>To assess the comparative efficacy of sertraline versus venlafaxine XR on measures of quality
      of life.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00644982</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Pfizer CT.gov Call Center</name>
      <address>Pfizer</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>